Phase 2 Study of Glecirasib Meets Primary End Point in KRAS G12C-Mutant NSCLC
A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an encouraging overall response rate.